Βιβλιογραφία Alzheimer

Υπό του Δρ. Δημητρίου Ν. Γκέλη - MD, ORL, DDS, PhD, Medical Life Coach, Αικατερίνης Γκέλη - MD Ιατρός Ακτινολόγος

Curcugkel: Μπορείτε να αγοράσετε το προϊόν, online, μέσω της ιστοσελίδας pharmagel.gr ακολουθώντας τον παρακάτω σύνδεσμο:

Αγορά Curcugkel

1. Insel PS1, Mattsson N2, Donohue MC3, Mackin RS4, Aisen PS5, Jack CR Jr6, Shaw LM7, Trojanowski JQ7, Weiner MW8; Alzheimer's Disease Neuroimaging Initiative. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2014 Dec 9. pii: S1552-5260(14)02869-6. doi: 10.1016/j.jalz.2014.11.002. [Epub ahead of print]

2. Martin N Rossor, Nick C Fox, Catherine J Mummery, Jonathan M Schott, Jason D Warren The diagnosis of young-onset dementia. Lancet Neurol. Author manuscript; available in PMC 2010 September 30.

3. Viola KL1, Sbarboro J1, Sureka R1, De M2, Bicca MA3, Wang J1, Vasavada S1, Satpathy S4, Wu S4, Joshi H2, Velasco PT1, MacRenaris K5, Waters EA5, Lu C1, Phan J1, Lacor P1, Prasad P6, Dravid VP7, Klein WL8. Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat Nanotechnol. 2014 Dec 22. doi: 10.1038/nnano.2014.254. [Epub ahead of print]

4. Khundakar AA1, Thomas AJ1. Neuropathology of Depression in Alzheimer's Disease: Current Knowledge and the Potential for New Treatments. J Alzheimers Dis. 2014 Sep 10. [Epub ahead of print]

5. Mah L1, Binns MA2, Steffens DC3; Alzheimer's Disease Neuroimaging Initiative. Anxiety Symptoms in Amnestic Mild Cognitive Impairment Are Associated with Medial Temporal Atrophy and Predict Conversion to Alzheimer Disease. Am J Geriatr Psychiatry. 2014 Oct 29. pii: S1064-7481(14)00306-6. doi: 10.1016/j.jagp.2014.10.005. [Epub ahead of print]

6. Farrell MT1, Zahodne LB, Stern Y, Dorrejo J, Yeung P, Cosentino S. Subjective word-finding difficulty reduces engagement in social leisure activities in Alzheimer's disease. J Am Geriatr Soc. 2014 Jun;62(6):1056-63. doi: 10.1111/jgs.12850. Epub 2014 Jun 2.

7.Mangialasche F1, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther. 2012 Feb 13;4(1):6. doi: 10.1186/alzrt104.

8. Lykouras L¹, Gournellis R. Behavioral and psychological symptoms of dementia and their management.Psychiatriki. 2011 Jan-Mar;22(1):24-33.

9. Koppel J¹, Greenwald BS². Optimal treatment of Alzheimer's disease psychosis: challenges and solutions. Neuropsychiatr Dis Treat. 2014 Nov 24;10:2253-62. doi: 10.2147/NDT.S60837. eCollection 2014.

10. Duyckaerts C, Panchal M, Delatour B, Potier MC. Morphologic and molecular neuropathology of Alzheimer's disease.]Ann Pharm Fr.2009 Mar;67(2):127-35. Epub 2009 Mar 5

11. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. . ActaNeuropathol. 2009 Jul;118(1):5-36. Epub 2009 Apr 21.

12. Kanamaru T1, Kamimura N2, Yokota T1, Iuchi K1, Nishimaki K1, Takami S3, Akashiba H3, Shitaka Y3, Katsura K4, Kimura K4, Ohta S1. Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer's disease. Neurosci Lett. 2014 Dec 18. pii: S0304-3940(14)00978-1. doi: 10.1016/j.neulet.2014.12.033. [Epub ahead of print]

13. Yang SY¹, Weng PH², Chen JH³, Chiou JM⁴, Lew-Ting CY⁵, Chen TF⁶, Sun Y⁷, Wen LL⁸, Yip PK⁹, Chu YM¹⁰, Chen YC¹¹. Leisure activities, apolipoprotein E e4 status, and the risk of dementia. J Formos Med Assoc. 2014 Nov 4. pii: S0929-6646(14)00269-1. doi: 10.1016/j.jfma.2014.09.006. [Epub ahead of print]

14. Hall A¹, Mattila J, Koikkalainen J, Lötjonen J, Wolz R, Scheltens P, Frisoni G, Tsolaki M, Nobili F, Freund-Levi Y, Minthon L, Frölich L, Hampel H, Visser PT, Soininen H. Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Curr Alzheimer Res. 2014 Dec 18. [Epub ahead of print]

15. Sastre M1, Richardson JC, Gentleman SM, Brooks DJ. Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr Alzheimer Res. 2011 Mar;8(2):132-41.

16. Peskind ER1, Li G2, Shofer JB3, Millard SP3, Leverenz JB4, Yu CE5, Raskind MA1, Quinn JF6, Galasko DR7, Montine TJ8.

Influence of lifestyle modifications on age-related free radical injury to brain. JAMA Neurol. 2014 Sep;71(9):1150-4. doi: 10.1001/jamaneurol.2014.1428.

17. Okonkwo OC1, Schultz SA2, Oh JM2, Larson J2, Edwards D2, Cook D2, Koscik R2, Gallagher CL2, Dowling NM2, Carlsson CM2, Bendlin BB2, LaRue A2, Rowley HA2, Christian BT2, Asthana S2, Hermann BP2, Johnson SC2, Sager MA2. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014 Nov 4;83(19):1753-60. doi: 10.1212/WNL.0000000000000964. Epub 2014 Oct 8.

18. Zhou S, Zhou R, Zhong T, Li R, Tan J, Zhou H1. Association of smoking and alcohol drinking with dementia risk among elderly men in china. Curr Alzheimer Res. 2014;11(9):899-907.

19. Thorin E1.Hypertension and Alzheimer disease: another brick in the wall of awareness. Hypertension. 2015 Jan;65(1):36-8. doi: 10.1161/HYPERTENSIONAHA.114.04257. Epub 2014 Oct 20.

20. Wood WG1, Li L, Müller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem. 2014 May;129(4):559-72. doi: 10.1111/jnc.12637. Epub 2014 Jan 2.

21. Li JG1, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol. 2014 Jun;75(6):851-63. doi: 10.1002/ana.24145. Epub 2014 May 28.

22. Hu N1, Yu JT, Tan L, Wang YL, Sun L, Tan L. Nutrition and the risk of Alzheimer's disease. Biomed Res Int. 2013;2013:524820. doi: 10.1155/2013/524820. Epub 2013 Jun 20.

23. Kamer AR1, Pirraglia E2, Tsui W2, Rusinek H3, Vallabhajosula S4, Mosconi L2, Yi L2, McHugh P2, Craig RG5, Svetcov S6, Linker R6, Shi C6, Glodzik L2, Williams S2, Corby P7, Saxena D8, de Leon MJ2. Periodontal disease associates with higher brain amyloid load in normal elderly. . Neurobiol Aging. 2014 Nov 5. pii: S0197-4580(14)00704-0. doi: 10.1016/j.neurobiolaging.2014.10.038. [Epub ahead of print]

24. Dufouil C1, Seshadri S2, Chêne G1. Cardiovascular risk profile in women and dementia. J Alzheimers Dis. 2014 Jan 1;42(0):S353-63. doi: 10.3233/JAD-141629.

25. Nguyen JC¹, Killcross AS², Jenkins TA¹. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014 Nov 19;8:375. doi: 10.3389/fnins.2014.00375. eCollection 2014.

26. Richardson JR¹, Roy A², Shalat SL¹, von Stein RT², Hossain MM¹, Buckley B², Gearing M³, Levey AI⁴, German DC⁵. Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol. 2014 Mar;71(3):284-90. doi: 10.1001/jamaneurol.2013.6030.

27. Okun MS1, DeLong MR, Hanfelt J, Gearing M, Levey A. Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology. 2004 Feb 10;62(3):411-3.

28. Richardson JR. Testosterone as the missing link between pesticides, Alzheimer disease, and Parkinson disease--reply. JAMA Neurol. 2014 Sep;71(9):1190. doi: 10.1001/jamaneurol.2014.1814.

29. Yasuno F1, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Kosaka J, Kudo T, Iida H, Kishimoto T. Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study. Int J Geriatr Psychiatry. 2014 Nov 26. doi: 10.1002/gps.4235. [Epub ahead of print]

30. Henderson VW¹ Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease. Climacteric. 2014 Dec;17 Suppl 2:38-46. doi: 10.3109/13697137.2014.929650. Epub 2014 Aug 17.

32. Gabryelewicz T. Pharmacological treatment of behavioral symptoms in dementia patients. Przegl Lek. 2014;71(4):215-20.

33. Broadstock M1, Ballard C, Corbett A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Εxpert Opin Pharmacother. 2014 Sep;15(13):1797-810. doi: 10.1517/14656566.2014.936848. Epub 2014 Jul 3.

34. Wu S1, Ding Y2, Wu F3, Li R1, Hou J4, Mao P5. Omega-3 fatty acids intake and risks of dementia and Alzheimer's disease: A meta-analysis. Neurosci Biobehav Rev. 2015 Jan;48C:1-9. doi: 10.1016/j.neubiorev.2014.11.008. Epub 2014 Nov 21.

35. Schlögl M1, Holick MF2. Vitamin D and neurocognitive function. ClinIntervAging. 2014 Apr 2;9:559-68. doi: 10.2147/CIA.S51785. eCollection 2014.

36. Littlejohns TJ1, Henley WE1, Lang IA1, Annweiler C1, Beauchet O1, Chaves PH1, Fried L1, Kestenbaum BR1, Kuller LH1, Langa KM1, Lopez OL1, Kos K1, Soni M1, Llewellyn DJ2. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014 Sep 2;83(10):920-8. doi: 10.1212/WNL.0000000000000755. Epub 2014 Aug 6.

37. AnnweilerC¹, DursunE, FéronF, Gezen-AkD, KalueffAV, LittlejohnsT, LlewellynDJ, MilletP, ScottT, TuckerKL, YilmazerS, BeauchetO. 'Vitamin D and cognition in older adults': updated international recommendations. J Intern Med. 2015 Jan;277(1):45-57. doi: 10.1111/joim.12279. Epub 2014 Jul 19.

38. Chaves M1, Toral A, Bisonni A, Rojas JI, Fernández C, Basallo MJ, Matusevich D, Cristiano E, Golimstok A. Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease.Vertex. 2014 Mar-Apr;25(114):85-91.

39. Annweiler C, Beauchet O. Possibility of a New Anti-Alzheimer's Disease Pharmaceutical Composition Combining Memantine and Vitamin D. Drugs Aging. 2012 Feb 1;29(2):81-91.

40. Chaves M¹, Toral A, Bisonni A, Rojas JI, Fernández C, Basallo MJ, Matusevich D, Cristiano E, Golimstok A. [Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease]. Vertex. 2014 Mar-Apr;25(114):85-91.

41. Clarke R1, Bennett D1, Parish S1, Lewington S1, Skeaff M1, Eussen SJ1, Lewerin C1, Stott DJ1, Armitage J1, Hankey GJ1, Lonn E1, Spence JD1, Galan P1, de Groot LC1, Halsey J1, Dangour AD1, Collins R1, Grodstein F1; on behalf of the B-Vitamin Treatment Trialists’ Collaboration. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014 Jun 25;100(2):657-666. [Epub ahead of print]

42. Yang M1, Xu DD, Zhang Y, Liu X, Hoeven R, Cho WC. A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analyses of intervention effect of ginkgo. Am J Chin Med. 2014;42(3):505-21. doi: 10.1142/S0192415X14500335.

43. Tyszka-Czochara M, Grzywacz A, Gdula-Argasińska J, Librowski T, Wiliński B, Opoka W. The role of zinc in the pathogenesis and treatment of central nervous system (CNS) diseases. Implications of zinc homeostasis for proper CNS function. Acta Pol Pharm. 2014 May-Jun;71(3):369-77.

44. Hori Y1, Matsuda O, Ichikawa S. Olfactory function in elderly people and patients with Alzheimer's disease. Psychogeriatrics. 2014 Dec 17. doi: 10.1111/psyg.12092. [Epub ahead of print]

45. Hamaguchi T1, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther. 2010 Oct;16(5):285-97. doi: 10.1111/j.1755-5949.2010.00147.x.

46. McClureR¹, YanagisawaD², StecD³, AbdollahianD⁴, KoktyshD⁵, XhillariD⁶, JaegerR⁶, StanwoodG⁷, ChekmenevE⁸, TooyamaI², GoreJC⁹, PhamW¹⁰. Inhalable Curcumin: Offering the Potential for Translation to Imaging and Treatment of Alzheimer's Disease. J Alzheimers Dis. 2014 Sep 16. [Epub ahead of print]

47. Lim GP et al. The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse. The Journal of Neuroscience, 1 November 2001, 21(21): 8370-8377

48. Ono K¹, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res. 2004 Mar 15;75(6):742-50.

49. DiSilvestro RA¹, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012 Sep 26;11:79. doi: 10.1186/1475-2891-11-79.

50. Progression of Brain Ageing, Criteria for Preclinical Alzheimer’s Disease, International Conference on Alzheimer’s Disease, September 25, 2010.

51. Shoba G¹, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 May;64(4):353-6.

52. Antony B¹, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin. IndianJPharmSci. 2008 Jul-Aug;70(4):445-9. doi: 10.4103/0250-474X.44591.

53. SasakiH¹, SunagawaY, TakahashiK, ImaizumiA, FukudaH, HashimotoT, WadaH, KatanasakaY, KakeyaH, FujitaM, HasegawaK, MorimotoT. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5.

54. DiSilvestro RA¹, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012 Sep 26;11:79. doi: 10.1186/1475-2891-11-79.

55. Nahar PP1, Slitt AL, Seeram NP. Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations. J Med Food. 2014 Dec 9. [Epub ahead of print]

56. Cox KH1, Pipingas A1, Scholey AB2. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2014 Oct 2. pii: 0269881114552744. [Epub ahead of print]
57. Cuomo J¹, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. JNatProd. 2011 Apr 5;74(4):664-9. doi: 10.1021/np1007262.Epub2011Mar 17.

58. Schiborr C, Kocher, A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol. Nutr. Food Res. 2014, 0, 1–12.

Τα αναγραφόμενα στο παραπάνω άρθρο είναι επιστημονική ενημέρωση των ιατρών και των λοιπών επιστημόνων υγείας και δεν αποτελούν μέσα διάγνωσης ή αντιμετώπισης ή πρόληψης ασθενειών, ούτε αποτελούν ιατρική συμβουλή για ασθενείς. Την ευθύνη της διάγνωσης, θεραπείας και πρόληψης των ασθενειών τις έχει μόνον ο θεράπων ιατρός του κάθε ασθενούς, αφού πρώτα κάνει προσεκτικά ακριβή διάγνωση. Γιαυτό συνιστάται η αποφυγή της αυθαίρετης εφαρμογής ιατρικών πληροφοριών από μη ιατρούς. Τα συμπληρώματα διατροφής δεν είναι φάρμακα, αλλά χορηγούνται συμπληρωματικά με τις αποδεκτές υπό της ιατρικής επιστήμης θεραπείες ή θεραπευτικές τεχνικές και μεθόδους, υπό ιατρική καθοδήγηση, παρακολούθηση και ευθύνη.

Δήλωση: Η ιστοσελίδα www.curcumin.gr έχει βασιστεί στις ιατρικές γνώσεις και απόψεις του Δρ Δημητρίου Ν. Γκέλη, οι οποίες είναι πάντοτε βιβλιογραφικά τεκμηριωμένες. Κάθε πληροφορία της ιστοσελίδας www.curcumin.gr δεν μπορεί να υποκαταστήσει την προσωπική σχέση οποιουδήποτε με το γιατρό του, ούτε αποτελεί ιατρική συμβουλή. Σκοπός του Δρ Γκέλη με την ιστοσελίδα www.curcumin.gr είναι να μοιραστεί τις γνώσεις και ιατρικές εμπειρίες του με όλους όσους επιθυμούν να διευρύνουν την ιατρική τους πληροφόρηση και να ενημερωθούν για θέματα διατήρησης της υγείας, του καλώς έχειν και προληπτικής ιατρικής.

Το παρόν άρθρο προστατεύεται από το Νόμο 2121/1993 και 4481/2017 για την πνευματική ιδιοκτησία. Η ολική ή μερική αντιγραφή του παρόντος επιστημονικού άρθρου χωρίς τη γραπτή έγκριση του Δρ Δημητρίου Ν. Γκέλη θεωρείται κλοπή πνευματικής ιδιοκτησίας και διώκεται βάσει της νομοθεσίας.

Curcugkel